Ipratropiumbromide/Salbutamol Neutec

Ipratropium bromide, the active ingredient in Ipratropiumbromide/Salbutamol Neutec, is a combination bronchodilator presented as an inhalation solution for inhalation use. It is indicated for the relief of bronchospasm in chronic obstructive pulmonary disease and asthma, providing rapid airway opening in patients with reversible airway obstruction.

GNH USA supplies Ipratropiumbromide/Salbutamol Neutec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and regulatory requirements across EU and global markets.

Ipratropium bromide/Salbutamol is a combination bronchodilator used in the management of obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): reduces bronchospasm and improves airflow during acute exacerbations. - Asthma: provides rapid relief of bronchoconstriction and improves breathing during attacks. - Acute bronchospasm: delivers fast bronchodilation to restore airway patency.

Ipratropiumbromide/Salbutamol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Tremor

Serious or Rare Side Effects: - Paradoxical bronchospasm - Cardiovascular events such as tachycardia or arrhythmia

When prescribing Ipratropiumbromide/Salbutamol, clinicians should consider several safety measures.

- Assess respiratory status: ensure patient has a confirmed diagnosis of COPD or asthma before use. - Monitor heart rate: β2‑agonists can increase heart rate, especially in patients with cardiac disease. - Use caution in patients with narrow‑angle glaucoma: anticholinergic component may increase intra‑ocular pressure. - Avoid concurrent use with other anticholinergic inhalers without medical supervision. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropiumbromide/Salbutamol can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): concurrent use can increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Other β2‑agonists: additive tachycardia or tremor may occur; dose adjustment may be needed. - Diuretics: may enhance hypokalemia caused by β2‑agonist activity. - Theophylline: combined use can increase risk of arrhythmias; monitor plasma levels.